# Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

> **NCT05218629** · PHASE2 · UNKNOWN · sponsor: **Qingdao Central Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Overall Survival

## Interventions

- **DRUG:** Anlotinib, PD-1 inhibitor

## Key facts

- **NCT ID:** NCT05218629
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218629, "Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05218629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*